ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO171

Lanthanum Dioxycarbonate Effectively Reduces Urinary Phosphate Excretion in Healthy Volunteers

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Gupta, Pramod, Unicycive Therapeutics Inc., Los Altos, California, United States
  • Khare, Atul, Unicycive Therapeutics Inc., Los Altos, California, United States

~600K kidney failure patients in the US undergo dialysis. Over 43% of these patients have phosphate(P) >5.5 mg/dL, leading to an increased risk of death. Patients rely on dietary restriction and phosphate(P) binders to avoid hyperphosphatemia. However, current P binders often do not achieve normal P levels and have high pill burdens (many large pills per day). A treatment that reduces pill burden while maintaining efficacy would improve patient adherence, quality of life and may be more likely to achieve P goals. Currently available 3000 mg/day lanthanum carbonate effectively reduces urinary P excretion by 236-468 mg/day. Lanthanum dioxycarbonate, RENAZORB(LDC), is a novel nanotechnology product that combines lanthanum, which has the highest binding capacity vs. other P binders, with a potentially smaller pill size that is swallowed with water rather than chewed. We present results of a phase 1 study evaluating LDC’s P binding capacity and tolerability.


A phase 1, double-blind, placebo-controlled study evaluated LDC’s P binding capacity and tolerability in 4 cohorts of 8 healthy adults. 3 separate LDC doses of 500 mg tablets were administered after meals for 5 days: 1500, 3000, 45000, 6000 mg/day.


All doses reduced the amount of P excreted in urine and increased the amount excreted in feces. Mean overall change in P excretion showed a statistically significant dose-response trend. LDC showed statistically significant mean reduction in urine P excretion with 3000 mg/day (p=0.0004), 4500 mg/day (p<0.0001), and 6000 mg/day (p=0.0001). All treatment-related adverse events (AEs) were mild. There were no severe/life-threatening AEs, serious AEs, deaths, or AEs leading to discontinuation.


LDC was effective in binding to dietary P and the efficacy was dose proportional. It was well tolerated. LDC may be a welcome choice for patients as it is effective and is a small swallowable pill.